Purpose Pregabalin is a gamma-aminobutyric acid (GABA) analogue approved for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder. As a GABA analogue, there has been some concern about an abuse liability. We aimed to investigate the possible abuse liability of pregabalin. Methods By applying a Bayesian data-mining algorithm to reports of possible drug abuse or addiction in the Swedish national register of adverse drug reactions (SWEDIS), we calculated the information component (IC) for pregabalin and reports of abuse and addiction. Results Out of 198 reports indicative of abuse or addiction to any drug, 16 concerned pregabalin. The IC became significantly elevated in the fourth quarter of 2008, rising to 3.99 (95% confidence interval 3.21-4.59) at the end of 2009. Conclusion Based on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse potential.
Introduction
Pregabalin is a gamma-aminobutyric acid (GABA) analogue used for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder (GAD) [1] . Although its precise mechanism of action is unclear, pregabalin decreases central neuronal excitability by binding to an auxiliary subunit (α 2 -δ protein) of a voltage-gated calcium channel on neurons in the central nervous system and reduces the release of several neurotransmitters, including glutamate, noradrenaline and substance P.
In the European Union as well as in the US, pregabalin was first approved for the treatment of epilepsy and peripheral neuropathic pain [1] . As a GABA analogue, there was some concern about the potential for addiction and drug abuse [1] . Premarketing trials had produced somewhat conflicting results in this respect. Studies in vitro did not show that the drug or its metabolites interacted with GABA A or GABA B receptors or inhibited GABA uptake or degradation, and studies in rats and monkeys found no propensity towards an abuse liability, although modest withdrawal signs upon discontinuation were observed in rats [1] . In addition, a dedicated clinical study in 15 recreational alcohol/sedative users found that pregabalin in therapeutic doses of 200-450 mg did not produce the same responses as diazepam, indicating that the drug did not have the profile of a prototypic drug of abuse, although it did produce subjective effects on a wide variety of measures that were different from placebo [1] . Consequently, the potential for drug abuse or physical dependence for pregabalin was assessed to be low at the time of marketing authorisation [1] . It was noted, however, that euphoria occurred as an adverse event in clinical trials among 1-10% of patients depending on dose, compared with 0.5% for placebo [1] . Other adverse events such as depersonalisation, nervousness, abnormal thinking and amnesia, symptoms that may reflect benzodiazepine-like adverse events, were also observed [1] .
In later clinical trials in patients with central neuropathic pain and in patients with GAD, euphoria as an adverse event was also reported to be common for pregabalin [1] , and assessments of withdrawal symptoms in clinical trials of GAD showed a profile similar to that of lorazepam [1] , especially in the 600-mg/day dosage. There was, however, no indication of significant dose escalation in open-label trials [1] .
An essential feature of effective risk management for drugs with an uncertain abuse liability is post-marketing surveillance that can detect the emergence of an abuse problem before the abuse of the medication becomes a major public health problem. Addiction is not labelled in the European Summary of Product Characteristics (SPC) for pregabalin, but is included as a rare adverse drug reaction (ADR) on the US label [2, 3] . As the question of the possible abuse potential of pregabalin is currently unsolved, we conducted a database analysis of reports of possible drug abuse or addiction to pregabalin in the Swedish national register of adverse drug reactions (SWEDIS) [4] .
Materials and methods
At the end of 2009, SWEDIS contained some 100,000 spontaneous reports submitted since 1965 by Swedish physicians to the Swedish Medical Products Agency (MPA). A Swedish dictionary is used for coding ADRs, built on a three-level hierarchical structure developed by the MPA [4] . The first level is the system organ class, followed by group terms, and finally preferred terms. The dictionary holds a little over 1,000 preferred terms.
The information in a report consists of patient demographics, reported ADRs, medication and a case narrative, often accompanied by copies of medical charts. All reports are reviewed by the MPA and a causality assessment is made, i.e. medicines can be listed as being suspected of having caused the reaction or as concomitant medication not related to the ADR. Drugs are coded with the WHO Collaborating Centre for Drug Statistics Methodology International Anatomical Therapeutic Chemical (ATC) classification [5] . To assess whether cases of possible drug abuse or addiction to pregabalin have been more commonly reported than expected, we calculated the information component (IC) [6] for the preferred terms "addiction", "drug addiction", "dependence", "tolerance increased" and "drug abuse" as a group. As some reports indicative of abuse may sometimes be coded with the terms "intoxication", "overdose", or "pathological inebriation", we also manually scanned all such reports for every drug in SWEDIS (n=718, of which 9 included pregabalin as a suspected drug) and included such reports in the calculations. In this respect, we only included reports in which the reporting physician had clearly stated that the patient had abused the suspected drug.
The IC is a logarithmic measure of association derived from a Bayesian data-mining algorithm used commonly in pharmacovigilance practice for the detection of potential safety signals [6] . An IC of 0 results from drug-event combinations for which the number of observed cases is the same as that which might be expected from the overall reporting in the dataset. Positive values represent combinations reported more frequently and negative values more infrequently than expected. Confidence intervals (CIs) of the IC (IC ±2 standard deviations) are calculated to account for sampling variability. We have previously shown that this methodology can be applied to SWEDIS with a near 80% probability for signalled drug-event combinations to be correctly labelled [4] . As reports before 1980 often contained only limited information, we restricted the analysis to reports entered into the database from 1980 until the end of 2009. As a significant proportion (15%) of ADR, adverse drug reaction; ADHD, attention deficit/hyperactivity disorder the reports concerned ADRs from vaccines (ATC class J07) and since such medicinal products are not associated with an abuse potential, we excluded these from the dataset. All statistical calculations were performed in Microsoft Excel 2007 (Microsoft Corporation).
Results
Out of 82,714 reports in SWEDIS during the study period, a total of 198 reports indicative of abuse or addiction to any drug were identified, of which 16 concerned pregabalin (Tables 1, 2) . Three of the reports for pregabalin were received from the same reporter, and the other 13 from single reporters across Sweden. The evolution of the IC with the 95% CI over time for pregabalin is shown in Fig. 1 reports. An overview of relevant data from these reports can be found in Table 3 . The median age of the patients was 29 years (range 18-51, age unknown for one case) and included 9 men and 7 women. The reported maximum daily doses ranged from 300 to 4,200 mg (median 1,000 mg), mostly taken as single doses. Six reports were coded as "drug abuse" and included one patient who injected pregabalin after dissolving the substance in water, and one patient who nasally inhaled the drug after crushing the contents of the capsules. Feelings of becoming "high" or of "a nice benzodiazepine effect" were described. Four reports were coded as "intoxication", in which patients reported having taken pregabalin to "get high" or described an effect similar to that of an "amphetamine trip" with euphoria. Two reports were coded as "dependence" and described feelings of being "high" and hospitalisations for detoxification. Two reports were coded as "tolerance increased" where patients increased their doses above the maximum recommended (1,200 and 3,000 mg/day) because of the waning of effect. One report was coded as "drug addiction" in which the patient described a feeling of becoming "high" with a sensation of flying. The last case was coded as "pathological inebriation" in which the patient reported using pregabalin to potentiate the effect of alcohol. Out of the 16 cases, 13 included a history of past or current substance abuse, and 2 patients reported selling part of their prescribed medication on the black market. The indication for which pregabalin had been prescribed was mostly unknown, but was reported as non-specified anxiety in 5 cases, and non-specified pain and GAD in 1 case.
Discussion
This is the first post-marketing study to show a signal of an abuse liability for pregabalin. As is common for a drug with an abuse liability, risk factors include a history of substance abuse, which was present in 13 out of 16 of the reports in SWEDIS. With a structure and pharmacodynamic profile similar to that of pregabalin, gabapentin would also be expected to exhibit a similar signal. However, we have found no case indicative of abuse or addiction to gabapentin in SWEDIS (data not shown). This difference may be due to pharmacodynamic differences, differences in reporting propensity or differences in the indications for use. Pregabalin is approved for the treatment of GAD, whereas gabapentin is not [7] , and while the indication for use was mostly unknown for the 16 cases described herein, it is of note that anxiety was the reported indication among the 6 cases where such information was provided, suggesting an association between abuse liability and indication, as has been described previously [8] .
Some limitations with signals derived from data-mining studies should be discussed. Data-mining methods in pharmacovigilance practices provide signals and not evidence of safety problems [6] . Thus, the present finding of a possible abuse liability for pregabalin should be considered as a signal that needs further testing in other materials. A potential source of bias is media attention concerning the drug-event combination in question, i.e. media attention may stimulate reporting, resulting in exaggerated signals. However, there has been no such attention regarding pregabalin and abuse in Sweden during the period of the present study, nor any communications from regulatory authorities regarding such a potential. Another conceivable source of bias is when a drug is often co-prescribed with another drug, which in turn is strongly associated with a particular ADR. In this situation, the drug under study may be suspected to cause the ADR, when in fact it is an innocent bystander. In the present study, however, pregabalin was the only suspected drug in 13 out of 16 cases, thereby rendering this possibility unlikely. Under-reporting of ADRs indicative of abuse might also introduce bias if this is selective for some drugs, e.g. for older drugs compared with newer. It is not possible to fully exclude such a possibility, but it would seem unlikely that this type of bias would result in a steadily increasing signal as presented in this report.
Conclusion
In Sweden, use of pregabalin is rapidly increasing and was 9.3 million defined daily doses (DDDs) in 2009, compared with 4.6 million in 2007. Based on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse liability and that further studies are urgently needed to characterise its extent and nature.
